Digilab Genomic Solutions(R) Has Entered Into Supply/Reseller Agreement with Applied Biosystems

HOLLISTON, Mass. — Digilab Genomic Solutions(R) (DGS) today announced it has entered into a supply and reseller agreement with Applied Biosystems. According to the agreement, DGS will supply HydroShear(R), a DNA shearing device for library preparation, to Applied Biosystems. Applied Biosystems will offer the HydroShear device with its SOLiD(TM) System — the company’s genetic analysis platform.

The HydroShear device uses hydrodynamic shearing forces to fragment DNA strands. With the HydroShear device, virtually any source of DNA at any concentration can be randomly fragmented to within two-fold size distribution – ideal for the generation of genetic analysis sequencing library preparation. The Digilab Genomic Solutions process delivers reproducible results independent of operator variability or time of the experimental procedure.

David Giddings, President and CEO of Digilab(R) remarked, “Applied Biosystems choice of DGS’ Digilab Genomic Solutions sample preparation for the SOLiD System offers the simplest, most reproducible, and most controllable method available for generating random DNA fragments for customers interested in pursuing next-generation sequencing. It further validates the important role Digilab plays in providing a number of commercial partners the tools they require to meet the systems and solutions needs of their life sciences research and clinical laboratory customers.”

About Digilab Genomic Solutions, Inc.

Digilab Genomic Solutions (formerly Genomic Solutions, Inc) provides innovative robotic and automation equipment for the global life science and biotechnology research community. Digilab Genomic Solutions develops and manufactures instrumentation, software, and consumables serving genomics, proteomics and high-throughput drug discovery. Our products enable researchers to perform complex, high volume experiments at a lower cost and in less time than traditional techniques.

Digilab; a global leader in molecular spectroscopy systems for over 40 years focusing on sample preparation, bioinformatics, and detection/analysis tools enabling solutions for the life sciences research and in-vitro diagnostics markets, including pharmaceutical and biotech industries, as well universities and governments. Digilab works with companies such as AstraZeneca, Boehringer Ingelheim, Merck & Co, Novartis, Novo Nordisk, Roche Diagnostics, Abbott Diagnostics, and Solvay Pharmaceuticals to address their needs for novel peptide biomarkers, diagnostics, and bioactive peptides for targeted therapeutics.

Digilab acquired SpectraCode in West Lafayette Indiana, a technology leader in Raman Spectroscopy and developer of systems/solutions for portable “point of need” molecular spectroscopy identification. Digilab concluded an exclusive OEM Distribution Agreement with Boehringer Ingelheim Microparts under which it commercializes Boehringer Ingelheim proprietary MicroSystems Technology (MST) Microspectrometers. Digilab and Boehringer Ingelheim also have a cooperation to bring point of need molecular spectroscopy devices to the marketplace. Digilab acquired BioVisioN GmbH, now Digilab Peptidomics(R), has developed and commercializes internationally patented Peptidomics products and services.

Digilab MAIA Scientific develops instrumentation and software for high information content screening: the MIAS-2 microscopic readers and the eaZYX software. DMS’ innovative products combine unequaled flexibility, sensitivity and speed for automated analysis of cells, tissues, beads and or model organisms.

The addition of Digilab Genomic Solutions and MAIA Scientific to Digilab, Inc, has completed Digilab as the “Family of Life Science Solutions.”